According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it well for continued pharmaceutical innovation. If approved, depemokimab would be the first ultra ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

https://www.tipranks.com/news/the-fly/cigna-price-target-lowered-to-350-from-400-at-cantor-fitzgerald GSK (GSK) announced that the European Medicines Agency, EMA, has ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I reiterate strong buy rating on GSK stock.

GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug ...